Biolase Technology (BLTI) Addresses Concerns
Biolase Technology (NASDAQ:BLTI - News) was informed by the Food and Drug Administration that the company adequately addressed the concerns outlined in the FDA's previous warning letter. The Irvine, Calif. maker of lasers used in dentistry and medicine had received a letter from the FDA earlier in the month following an inspection of its Irvine facility, warning that certain aspects of the manufacturing, packing, storage or installation of its devices were not in conformance with the FDA's good manufacturing practice requirements. The company said it now believes the issues are fully resolved.
posted by Stock Administrator @ 3:58 PM
0 Comments:
Post a Comment
<< Home